Innovation often happens behind closed doors. Across healthcare, technology, and business, dedicated teams develop solutions to complex problems. However, many of these advancements fail to reach the public. Without visibility, people who need these solutions the most remain unaware of their options. This gap between creation and professional and public awareness slows progress and limits the reach of new tools, especially in critical fields like dementia care.
World Impact Productions offers a solution to this visibility gap through its “Breakthroughs” Public Service Announcement (PSA) campaign. Produced by an award-winning, philanthropic team of film and television professionals, the series brings national and international attention to important organizations. Today, we sit down with Mark Allan, Founder and Executive Producer at World Impact Productions. We will discuss the vision behind the “Breakthroughs” series, how his team selects featured organizations like SkinIO, and why philanthropic media campaigns matter.
Q: World Impact Productions recently launched the “Breakthroughs” PSA campaign. What inspired you to use your platform to highlight new developments across different industries?
Mark Allan: What inspired Breakthroughs™ was a very simple observation: some of the most important advancements in the world are happening quietly, behind the scenes, inside companies, laboratories, hospitals, manufacturing facilities, research institutions, and innovation teams that most people have never heard of.
The problem is that innovation is moving faster than public understanding. In many cases, the science, technology, or solution already exists — but the public, professional communities, investors, policymakers, and decision-makers have not yet been given a clear, credible way to understand why it matters.
That is where we felt we could contribute. We’re not looking to create commercials. We’re using the PSA format to create public-interest education around meaningful advancements that may change lives, improve outcomes, expand access, or solve problems that deserve national attention. The goal is to help important work become understood — not hyped, not oversold, but understood.
Q: Your team consists of award-winning film and television professionals. How does this level of production quality change the way audiences receive these public service messages?
Mark Allan: Production quality changes trust. Audiences make judgments very quickly. If an important medical or scientific subject is presented in a flat, generic, low-quality way, people may unconsciously assume the idea itself is small, unproven, or unimportant. But when the message is produced with the seriousness, visual language, pacing, sound, and emotional clarity of a premium documentary or national broadcast feature, the audience receives the subject differently.
For us, quality is not cosmetic. It is part of credibility. If we are asking viewers to pay attention to a complex medical advancement, a new diagnostic model, a clean energy platform, or a breakthrough in manufacturing or biology, then the production has to honor the importance of the subject.
The right visuals, music, editing, and narrative structure can take a complicated idea and make it human. That is where high-level film and television professionals make a real difference. They help turn complexity into understanding — and understanding is where action begins.
Q: The campaign recently featured SkinIO for their work in early detection of Skin Cancer. What specific criteria do you look for when selecting an organization for the series?
Mark Allan: We look for several things, and they all matter.
First, the subject has to have genuine public-interest value. It cannot simply be a company wanting exposure. There has to be a real problem affecting people, families, patients, communities, industries, or society.
Second, the organization has to be credible enough to represent the topic. That means there should be meaningful validation, a real solution, responsible leadership, and a clear ability to explain the advancement without exaggeration.
Third, the story has to be understandable. Some breakthroughs are important but impossible to communicate clearly in a few minutes. We look for organizations where the problem is real, the solution is meaningful, and the audience can quickly understand why it matters.
SkinIO stood out because the public-health issue is immediately clear: skin cancer detection depends on people being screened early enough, but access can be a barrier. The SkinIO story allowed us to talk about early detection, access, technology, physician review, and patient empowerment in a way that is practical, relevant, and deeply human.
Q: Skinio uses AI-powered skin imaging and mole-mapping technology designed for early skin cancer detection. Why did this specific approach stand out as a necessary addition to healthcare?
Mark Allan: Because the most important breakthrough is often not only the treatment — it is getting people to the right point of care sooner.
Skin cancer is one of those conditions where time matters. People may notice something and delay. Or they may not notice anything at all. Or they may want to be checked but face difficulty getting a timely dermatology appointment. That access gap is where technology can play a very meaningful role.
What stood out about SkinIO is that it helps move the first step closer to the patient. Guided imaging, mole mapping, AI-supported analysis, and dermatologist review create a pathway that can help people move from uncertainty to action faster.
Importantly, this is not about replacing physicians. That would be the wrong message. It is about supporting earlier awareness, better triage, and a clearer path to professional care. That is exactly the kind of healthcare innovation the public needs to understand: technology working with clinicians, not instead of them.
Q: The “Breakthroughs” campaign reaches a national and international audience. What primary action do you hope viewers take after seeing these public service announcements?
Mark Allan: The first action is awareness. We want people to stop and say, “I didn’t realize this was possible,” or “I didn’t understand why this mattered.”
But awareness is only the beginning. For a public-health PSA, we want viewers to take appropriate action — ask a doctor, get screened, learn more, talk to a family member, or pay attention to a symptom they might otherwise dismiss.
For professional audiences, the action may be different. A physician, hospital leader, investor, policymaker, researcher, or industry executive may see the same PSA and recognize that a particular advancement deserves further evaluation, partnership, support, or adoption.
That is the power of this format. A good PSA can reach the general public emotionally while also signaling to professional communities that this is a serious issue worthy of attention.
Our hope is that viewers do not just watch and move on. We want them to understand, discuss, question, share, investigate, and act.
Q: Looking forward, what future sectors or types of advancements do you plan to feature in upcoming installments of the “Breakthroughs” series?
Mark Allan: We are intentionally looking across sectors because real breakthrough work is not confined to one industry.
Healthcare will continue to be a major focus — especially early detection, precision diagnostics, rare disease, cancer care, neurotechnology, regenerative medicine, patient access, and technologies that help clinicians make better decisions.
But we are also looking closely at clean energy, advanced manufacturing, biomanufacturing, environmental remediation, data infrastructure, food systems, climate resilience, space, materials science, and other areas where specialized innovation is quietly reshaping the future.
What we are not interested in is simply featuring the most obvious companies or the loudest trends. We are much more interested in the under-recognized advancements that deserve broader understanding. The question we ask is always the same: If people understood this better, could it change behavior, improve outcomes, accelerate adoption, or create meaningful benefit?
If the answer is yes, then it usually belongs in Breakthroughs™.
Our discussion reveals the critical role the media plays in advancing public knowledge. By pairing high-quality production with philanthropic goals, the “Breakthroughs” series ensures that vital new tools gain the attention they deserve. Highlighting programs like virtual field trips for dementia patients shows how targeted public service campaigns can directly connect people with life-improving resources.
As industries continue to evolve, the need to share these discoveries will only grow. Breakthroughs™ provides a necessary platform to bridge the gap between creators and the public. Their ongoing work guarantees that meaningful solutions will find their way to the communities that need them most.
To learn more, visit: psabreakthroughs.org